MedicineClinical Overview
Tiotropium Bromide Inhalation (9mcg MDI, 18mcg Rotacaps) is a long-acting muscarinic antagonist (LAMA) on the WHO Model List of Essential Medicines. It binds to muscarinic M1, M2, and M3 receptors, but dissociates extremely slowly from M3 receptors (dissociation half-life ~35 hours), delivering sustained 24-hour bronchodilation from a single daily dose. Reduces lung hyperinflation, improves exercise tolerance, and significantly decreases the frequency of COPD exacerbations. Indicated for long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD) and add-on maintenance in severe persistent asthma.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Inhale the powder from 1 capsule (18 mcg) once daily at the same time each day using the specialized DPI device (or 2 puffs once daily with Respimat/MDI). Swallow NEVER; capsules are for oral inhalation only.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Dry mouth (xerostomia in ~10-15%, mild and transient), pharyngitis, sinusitis, constipation, urinary tract infection, headache. Rare/Severe: Acute urinary retention, narrow-angle glaucoma, and paradoxical bronchospasm.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Do not swallow capsules. Once-daily dosing only. Keep inhalation device away from eyes. Contraindicated in severe hypersensitivity to atropine or milk proteins (lactose carrier). Caution in prostatic hyperplasia and glaucoma.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Tiotropium Bromide 18mcg + Formoterol Fumarate Dihydrate 12mcg Rotacaps
Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.
Tiotropium Bromide 18mcg + Formoterol Fumarate Dihydrate 12mcg + Ciclesonide 400mcg Rotacaps
Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.
Tiotropium Powder for Inhalation 18mcg Rotacaps
Tiotropium Bromide Inhalation (9mcg MDI, 18mcg Rotacaps) is a long-acting muscarinic antagonist (LAMA) on the WHO Model List of Essential Medicines. It binds to muscarinic M1, M2, and M3 receptors, but dissociates extremely slowly from M3 receptors (dissociation half-life ~35 hours), delivering sustained 24-hour bronchodilation from a single daily dose. Reduces lung hyperinflation, improves exercise tolerance, and significantly decreases the frequency of COPD exacerbations. Indicated for long-term, once-daily maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD) and add-on maintenance in severe persistent asthma.
Ciclesonide (200Mcg) + Formoterol (6Mcg) + Tiotropium (9Mcg) Inhaler
Tiotropium Bromide (18mcg) and Formoterol Fumarate (12mcg, with or without Ciclesonide 400mcg / Inhaler / Rotacaps) is a dual/triple bronchodilator therapy for advanced COPD and severe refractory asthma. Tiotropium is a long-acting muscarinic antagonist (LAMA) with prolonged M3 receptor dissociation kinetics (>36 hours); formoterol is a fast-acting LABA; ciclesonide is an on-site activated corticosteroid prodrug. Indicated for maintenance treatment of severe COPD and persistent severe asthma with frequent exacerbations.